Previous studies have shown that inhibiting the PI3K/AKT pathway can lead to the up-regulation and over-activation of RTKs, such as HER3 (ErbB3), IGF-1R or IR, aimed at maintaining the PI3K pathway in equilibrium in breast cancer or NSCLC [24,36,37]. This evidence concerns the gene ERBB3 and breast cancer.